I. Y. Mykhaloyko

I. Y. Mykhaloyko

Auto-generated profile, based on publicly available information

I. Y. Mykhaloyko

Івано-Франківський національний медичний університет, кафедра хірургічних хвороб, м. Івано-Франківськ, Україна

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2025 in Wiadomości Lekarskie
Verified
Journal Article
Closed access
OMOlga Jaroslavivna Mykhaloiko
Olga Jaroslavivna Mykhaloiko
VGViktoriya Anatolyivna Gryb
Viktoriya Anatolyivna Gryb
IFIvanna-Romana Mykolaivna Fabryka
Ivanna-Romana Mykolaivna Fabryka
OHOleksandra Ihorivna Hotsaniuk
Oleksandra Ihorivna Hotsaniuk
USUlyana Petrivna Shalamai
Ulyana Petrivna Shalamai
IMIgor Jaroslavovich Mykhaloiko
Igor Jaroslavovich Mykhaloiko
Aim: The purpose of the study is to study changes in Lp-PLA2 in the blood of patients in the early recovery period of atherothrombotic stroke depending on the degree of stenosis and type of atherosclerotic plaque.Material and methods: A clinical and laboratory analysis of 130 patients in the early recovery period of atherothrombotic stroke was conducted. Among those examined were 69 men and 61 women aged (60.42±7.4) years. The control group consisted of 30 practically healthy persons (16 men and 14 women) without a history of severe somatic pathology, aged (58.7±6.3) years. Ultrasound scanning of the vessels of the neck was performed on a Siemens Acuson X 300 device. The amount of lipoprotein-associated phospholipase A2 (Lp-PLA2) was determined by the immunoenzymatic method. STATISTICA 8 software was used for statistical processing.Results: In all examined patients, an increase in the content of Lp-PLA2 in the blood up to 260 (220.4; 295.7) ng/ml was found compared to individuals of the control group (p<0.05). Increased levels of Lp-PLA2 in stroke patients were associated with an increased degree of atherosclerotic stenosis and depended on the type of atherosclerotic plaque, reflecting its instability.Conclusions: Increased concentrations of Lp-PLA2 in patients with cerebral atherosclerosis can be considered as circulating biomarkers of atherosclerotic plaque vulnerability. Patients in the early recovery period of an ischemic stroke with a soft atherosclerotic plaque according to ultrasound data in combination with an increase in Lp-PLA2 indicators in the blood belong to the group of high risk of developing a repeated stroke.

28 June 2026 in Art of Medicine
Verified
Journal Article
Open access
PDF file
IMI.S. Mykhaloiko
I.S. Mykhaloiko
RYR.I. Yatsyshyn
R.I. Yatsyshyn
IMI.YA. Mykhaloiko
I.YA. Mykhaloiko
Nephrotic syndrome (NS) is associated with a significantly increased risk of thromboembolic complications resulting from profound disturbances of the hemostatic system. One of the central mechanisms underlying this hypercoagulable state is the imbalance between procoagulant and anticoagulant factors, particularly the depletion of natural anticoagulants such as antithrombin III (AT-III), protein C, and protein S. These proteins play a crucial physiological role in regulating coagulation and preventing excessive thrombin generation. A deficiency in these factors can promote the emergence of a hypercoagulable (prothrombotic) state that is frequently seen in patients with NS. This study was designed to evaluate the concentrations of physiological anticoagulants in patients with NS and to investigate their association with laboratory markers of hypercoagulability and disease severity. The cross-sectional study included 76 patients with primary glomerulonephritis (GN) accompanied by NS who were treated between 2022 and 2024, as well as a control group of 40 apparently healthy individuals. Hemostatic parameters were assessed using chromogenic and clot-based functional assays, and statistical analysis included correlation and multivariable regression models. The results demonstrated clear evidence of coagulation system activation in patients with NS. Levels of D-dimer and fibrinogen were significantly higher compared with the control group, reflecting increased thrombin generation and fibrin turnover. At the same time, significant reductions in the activity of natural anticoagulants were observed. AT-III levels were markedly decreased in patients with NS, and similar reductions were detected for protein C and free protein S. Correlation analysis revealed that AT-III showed the strongest associations with markers of NS activity and hypercoagulability. AT-III levels demonstrated a positive correlation with serum albumin and negative correlations with proteinuria, D-dimer, and fibrinogen. These findings suggest that both the severity of NS and the activation of coagulation pathways contribute to depletion of endogenous anticoagulant mechanisms. Multivariable regression analysis identified serum albumin and D-dimer levels as independent predictors of reduced AT-III activity. Hypoalbuminemia, reflecting urinary protein loss and disease severity, was strongly associated with decreased AT-III levels, while elevated D-dimer indicated ongoing activation of the coagulation cascade. Overall, the study demonstrates that nephrotic syndrome is characterized by a pronounced prothrombotic hemostatic profile involving both activation of coagulation and depletion of natural anticoagulants. Among the studied parameters, AT-III deficiency appears to represent the most prominent disturbance and may play a key role in the development of hypercoagulability in patients with NS. These findings highlight the potential clinical importance of assessing natural anticoagulant levels as biomarkers of thrombotic risk and may contribute to improved risk stratification and individualized prophylactic anticoagulation strategies in patients with NS.

10 December 2023 in Art of Medicine
Verified
Journal Article
Open access
PDF file
RYR.I. Yatsyshyn
R.I. Yatsyshyn
IMI.Ya. Mykhaloiko
I.Ya. Mykhaloiko
Резюме.  Метою даного дослідження була оцінка ефективності сулодексиду в лікуванні хворих на гломерулонефрит. Матеріали і методи. Проведено проспективне когортне дослідження за участю 125 пацієнтів із ГН, які перебували на лікуванні в Івано-Франківській обласній клінічній лікарні (Україна) у 2021-2022 роках. До дослідження були включені лише пацієнти з протеїнурією 0,3 – 3,5 г/добу, ХХН 1–3 стадії та діагнозом ГН. Під час дослідження всім пацієнтам проводили стандартне обстеження, яке включало загальноклінічні, біохімічні та інструментальні методи дослідження. Лікування хворих здійснювали згідно міжнародних рекомендацій щодо ведення пацієнтів з гломерулярними захворюваннями. Усі пацієнти були розподілені на 2 групи. 1 група отримувала базисну терапію, 2 група одержувала сулодексид у формі капсул для прийому всередину по 250 ліпопротеїнліпазних одиниць 2 рази на добу додатково до базисної терапії. Тривалість лікування становила 6 місяців. Не було суттєвих відмінностей у вихідних демографічних і клініко-лабораторних даних між двома досліджуваними групами. Ефективність лікування оцінювали за рівнем протеїнурії, ШКФ та частотою тромбоемболічних і серцево-судинних подій, що виникали протягом періоду спостереження. Результати. Проведене дослідження показало, що додаткове застосування сулодексиду протягом 6 місяців достовірно знижувало рівень протеїнурії у хворих на ГН. Оскільки швидкість клубочкової фільтрації залишалася стабільною або навіть зростала, зниження протеїнурії не можна пояснити зміною фільтраційної здатності нирок. Також нами відмічено достовірне зниження рівня фактора Віллебранда та тромбомодуліну в групі хворих, які додатково отримували сулодексид протягом 6 місяців. Висновки. Додаткове застосування сулодексиду у хворих на ГН статистично вірогідно знижувало рівень протеїнурії, запобігаючи прогресуванню ХХН. Аналіз статистичних даних показав, що застосування сулодексиду протягом 6 місяців статистично вірогідно знижує рівні тромбомодуліну та фактора Віллебранда у сечі хворих на ГН, що вказує на відновлення цілісності та функції ендотелію.

30 March 2023 in Clinical endocrinology and endocrine surgery
Verified
Journal Article
Open access
PDF file
VSV. D. Skrypko
V. D. Skrypko
OAO. Y. Atamanyuk
O. Y. Atamanyuk
STS. S. Tsybran
S. S. Tsybran
VBV. V. Boyko
V. V. Boyko
IMI. Y. Mykhaloyko
I. Y. Mykhaloyko
ІМІ. Я. Михалойко
І. Я. Михалойко
Objective — to improve the surgical treatment of patients with thyroid cancer with metastatic lesions of the neck lymph nodes by means of an individual approach to diagnostics, intraoperative imaging, and choice of optimal surgical technique. Materials and methods. The analysis involved results of examinations and treatment of 749 patients. The following was taken into account: complaints, thyroid and lymph nodes ultrasound, thyroid hormones level, results of general clinical examinations. Levels of parathyroid hormone, vitamin D, magnesium, total and ionic calcium were determined at the preoperative stage. In some cases, computer tomography results were included. A fine‑needle aspiration (FNA) biopsy was performed to all patients. Women prevailed: 607 from 749 (81.0%; 95% CI 78.0—83.8). The mean age of the patients was 51.3% (45.6—59.1) years. The causes of disease included: colloid nodular goiter 566 (75.6%; 95% CI 72.3—78.6), nodular (adenomatous) goiter with follicular neoplasm 72 (9.6%; 95% CI 7.6—12.0), papillary carcinoma 54 (7.2%; 95% CI 5.5—9.3), suspicious for papillary thyroid carcinoma (according to the cytology results) 17 (2.3%; 95% CI 1.3—3.6), medullary carcinoma 12 (1.6%; 95% CI 0.8—2.8), anaplastic thyroid cancer 6 (0.8%; 95% CI 0.3—1.7), other tumors 22 (2.9%; 95% CI 1.8—4.4). Statistical processing of the obtained results was carried out by using the standard program package «Statistica 6.0 for Windows» (StatSoft, USA). Results. Surgical interventions were performed in 89 of 749 (11.9%; 95% CI 9.7—14.4) patients with malignant tumors of the thyroid gland. The variety of surgical procedures performed on the thyroid gland: thyroidectomy performed in 81 of 89 patients (91%; 95% CI 83.1—96.0), hemithyroidectomy in 8 of 89 patients (9.0%; 95% CI 4.0—16.9). The reasons for the hemithyroidectomy: in 2 of 89 patients (2.2%; 95% CI 0.3—7.9) the diagnosis was not confirmed by express histological examination with suspicion for papillary thyroid carcinoma. In 6 other cases, single micro adenocarcinomas that ranged in size from 0.4 to 0.8 mm were found, without invasion into the tumor capsule, which was confirmed during a planned pathological examination. Lymphodisection of the central tissue, as an addition to thyroidectomy, was performed by us in 76 of 89 cases (85.4%; 95% CI 76.3—92.0). Metastatic lesions of the central tissue during pathological examination were found in 29 (32.6%; 95% CI 23.0—43.3) patients with papillary carcinoma, in 5 with medullary cancer (5.6%; 95% CI 1.8—12.6), in 6 cases with anaplastic thyroid cancer (6.7%; 95% CI 2.5—14.1). In 11 patients (12.4%; 95% CI 6.3—21.0) due to the metastatic spread to the platysma of the lateral triangle of the neck, its excision was performed. In 9 (10%; 95% CI 4.7—18.3) patients were performed thyroidectomy with sheath‑fascial excision (removal) of the neck tissue. The precession method was used to visualize the upper laryngeal nerve in order to prevent traumatization. The upper parathyroid glands served as the first anatomical landmark of the recurrent nerve, which were identified in 72 (80.9%; 95% CI 71.2—88.5) patients. Temporary unilateral vocal fold paresis was observed in 3 (3.4%; 95% CI 0.7—9.5) patients. Wound drainage was carried out separately by leaving micro‑drainage, for active aspiration, which was evacuated in 2 days. Соnclusions. One of the main prerequisites for the high‑quality performance surgery of thyroid gland is the precise nature of surgical manipulations with careful observance of tactical and technical requirements for a surgeon: timely identify and precisely mobilize. The choice of the final surgical intervention on lymphatic collectors in thyroid cancer is directly dependent on the preoperative and intraoperative pathological examination. However, given the substantial proportion of metastatic lesions of the central zone lymph nodes (level VI), the technical complexity of repeated operative interventions in this area, it is recommended to perform a preventive removal of the central fiber.

4 April 2026 in Art of Medicine
Verified
Journal Article
Open access
PDF file
ІМІ. C. Михалойко
І. C. Михалойко
РЯР. І. Яцишин
Р. І. Яцишин
ІМІ. Я. Михалойко
І. Я. Михалойко
The aim of this study was to evaluate the efficacy, safety, and potential pleiotropic effects of apixaban compared to warfarin in patients with nephrotic syndrome (NS) secondary to primary glomerulonephritis (GN). A prospective cohort study was conducted involving 65 adult patients with biopsy-proven primary GN presenting with NS. To prevent thromboembolic events, patients were assigned to two treatment groups: Group I (n = 32) received warfarin, and Group II (n = 33) received apixaban. The follow-up duration was 6 months, during which clinical and laboratory evaluations were performed at baseline, after 1 month, and after 6 months of therapy. Serum and urinary concentrations of inflammatory (IL-6, TNF-α), fibrotic (TGF-β₁) biomarkers, and thrombin were measured using enzyme-linked immunosorbent assay (ELISA). The primary endpoints included the incidence of thromboembolic and hemorrhagic events; secondary endpoints comprised changes in laboratory markers reflecting inflammation, fibrosis, and coagulation activity. Throughout the 6-month observation period, no thromboembolic complications were detected in either group, confirming the high efficacy of both anticoagulant regimens in thrombosis prevention. However, the incidence of hemorrhagic complications was significantly lower in the apixaban group (9.1 % vs 37.5 % in the warfarin group, p = 0.01). All bleeding episodes were minor — including epistaxis, gingival bleeding, and subcutaneous hematomas — and did not require discontinuation of therapy or hospitalization. Both groups showed a gradual reduction in serum and urinary IL-6, TNF-α, TGF-β₁, and thrombin levels, reflecting a decline in systemic and local inflammatory and coagulative activity. This effect was more pronounced and statistically significant in the apixaban group (p₂ < 0.05). After 6 months, patients on apixaban had a greater decrease in IL-6 and TNF-α, suggesting inhibition of pro-inflammatory cytokine pathways. A marked reduction in TGF-β₁ — a key marker of fibrosis — was also observed, indicating a potential antifibrotic effect. The decrease in urinary thrombin levels, particularly in the apixaban group, may reflect suppression of local thrombo-inflammatory processes at the glomerular microvascular level, thereby contributing to renal protection and stabilization of kidney function. In summary, apixaban proved to be an effective and safe agent for preventing thromboembolic complications in patients with NS associated with primary GN. Compared with warfarin, apixaban demonstrated a lower rate of minor bleeding and a more pronounced reduction in inflammatory, fibrotic, and coagulation biomarkers, supporting its potential pleiotropic properties. These results suggest that, beyond anticoagulation, apixaban may exert nephroprotective effects by modulating renal inflammation and fibrosis and improving microvascular homeostasis. Further large-scale, multicenter, randomized studies with longer follow-up and molecular analyses are needed to confirm these findings and elucidate the mechanisms underlying the pleiotropic effects of apixaban.

11 September 2026 in Clinical and Preventive Medicine
Verified
Journal Article
Open access
PDF file
OMOlga Ya. Mykhaloiko
Olga Ya. Mykhaloiko
IMIgor Ya. Mykhaloiko
Igor Ya. Mykhaloiko
Introduction. Despite the status of acetylsalicylic acid (ASA) as the “gold standard” for secondary stroke prevention, the prevalence of resistance to it varies from 5% to 65%.Aim. To identify the leading pathogenetic factors for the occurrence of recurrent ischemic events in patients with atherothrombotic stroke (ATS) against the background of standard secondary prevention and to scientifically substantiate the algorithm for choosing personalized antiplatelet therapy depending on individual sensitivity to antiplatelet agents.Materials and methods. A clinical and neurological examination of 200 patients (116 men, 84 women; mean age 60.4 ± 7.4 years) in the recovery period of ATS was performed. CT/MRI of the brain, ultrasound of extracranial vessels, EchoCG and 72-hour Holter ECG monitoring were performed. The functional activity of platelets was studied by optical aggregometry with the inducer adrenaline. Aspirin resistance (AR) was verified if the degree of aggregation exceeded 60%. Control group – 50 practically healthy individuals. Statistical analysis was performed in STATISTICA 8.0.Results. During the year of observation against the background of standard therapy (ASA, statins, antihypertensive, hypoglycemic agents) recurrence of ischemic stroke was recorded in 52 patients (26.0%). In 7.69% of cases (n = 4) the cause of the recurrent stroke was the transformation of the pathogenetic subtype of stroke from atherothrombotic to cardioembolic due to the detected paroxysmal atrial fibrillation. Among the remaining 48 individuals with confirmed atherothrombotic genesis of recurrence, AR was confirmed in 47.9% of cases (n = 23), while the degree of platelet aggregation was 85.4 [75.1; 97.2] %, which was 2.01 times higher than the control values (p < 0.01). The detected AR caused a revision of the antithrombotic strategy and the transition from ASA to clopidogrel (75 mg/day).Conclusions. The main factor in the ineffectiveness of standard secondary prevention in 47.9% of patients with recurrent ATS is laboratory resistance to ASA, which dictates the need for routine aggregometry. Verification of AR is the basis for correction of therapy by replacing ASA with clopidogrel, which provides stabilization of platelet hemostasis through an alternative biochemical mechanism.